Can BMAC Delay Knee Surgery? Alternatives to Knee Replacement

For many active adults over the age of 55 facing chronic osteoarthritis, discovering viable non-surgical alternatives to knee replacement is a top priority. When persistent knee pain, joint stiffness, and reduced mobility interfere with daily life, patients frequently ask whether bone marrow aspirate concentrate (BMAC) can safely postpone or avoid major joint replacement. In orthopaedic practice, BMAC is positioned precisely around this clinical goal: buying healthy, active years before definitive joint surgery becomes necessary.

At his practice in Lahore, consultant orthopaedic surgeon Dr Farooq Azam Khan provides the first hospital-based BMAC treatment in Lahore programme, offering patients an evidence-based biological approach to joint preservation. This article examines what published clinical research reveals about delaying knee replacement with BMAC, where the scientific boundaries lie, and when postponing surgery may actually be counterproductive.

BMAC as One of the Alternatives to Knee Replacement

Osteoarthritis is a progressive degenerative condition where joint cartilage gradually thins, accompanied by chronic synovial inflammation and subchondral bone remodelling. While total knee replacement is an exceptionally reliable operation for end-stage joint disease, many patients with moderate arthritis are reluctant to undergo major surgery if non-operative preservation remains feasible.

Traditional non-operative pathways include physiotherapy, weight optimisation, oral anti-inflammatory medications, and hyaluronic acid or platelet-rich plasma injections, as discussed in our comprehensive overview of alternatives to knee replacement. BMAC represents a more potent biological step within this continuum. By delivering concentrated autologous mesenchymal stem cells (MSCs), platelets, and anti-inflammatory cytokines directly into the joint space, BMAC alters the inflammatory biochemical environment, helping to reduce pain and maintain functional joint movement.

The 4-Year Evidence: What Pabinger et al. (2024) Demonstrated

The strongest published mid-term evidence examining whether BMAC can delay joint replacement comes from a prospective multi-centre study by Pabinger, Lothaller, and Kobinia, published in Scientific Reports (2024). The investigators evaluated intra-articular BMAC injections in 29 patients (37 knees) suffering from advanced knee osteoarthritis (15 knees with Kellgren–Lawrence grade III and 22 knees with grade IV):

• Sustained pain reduction: The mean WOMAC score improved from 40 ± 23 at baseline to 18 ± 18 at 4 years (p < 0.001).
• Functional recovery: The IKDC functional score improved from 56 ± 12 to 73 ± 13 over the same period (p < 0.001).
• Zero surgical conversions: Across the entire 4-year follow-up period, zero knees (0 of 37) progressed to total knee replacement surgery.
• High responder rate: 35 of 37 knees (95%) experienced meaningful score improvements, with benefits beginning in year 2 and persisting through year 4.

These findings provide encouraging evidence that BMAC can help patients with moderate-to-advanced joint wear maintain comfortable function for several years. However, this study must be interpreted alongside its documented scientific limitations: it lacked a blinded placebo control group, did not include comprehensive serial MRI cartilage scans, and had incomplete SF-36 data. Consequently, while BMAC can buy meaningful time, it cannot be framed as a permanent guarantee against future surgery.

What BMAC Cannot Do

A responsible surgical perspective requires transparency regarding the limitations of cellular therapies. As highlighted in international reviews such as Medicina (2025):

• Placebo findings: One randomised placebo-controlled trial reviewed in Medicina (2025) found no statistically significant difference in pain reduction between BMAC and saline injections (p > 0.09).
• No proven cartilage regrowth: While BMAC delivers potent anti-inflammatory signalling, there is no scientific proof that it regrows pristine articular cartilage in an arthritic knee.
• Unproven long-term disease modification: Without clinical trials extending to 5 or more years with serial MRI evaluations, it remains unproven whether BMAC permanently alters the natural progression of osteoarthritis.

BMAC should therefore be viewed as a joint-preserving therapeutic bridge that calms joint irritation and extends functional years, rather than a permanent substitute for reconstructive surgery. Full literature reviews are detailed in our complete guide to BMAC in Pakistan.

When Delaying Knee Replacement Is the Wrong Choice

While joint preservation is highly desirable, delaying definitive surgery indefinitely is not without risk. In certain clinical scenarios, attempting to postpone surgery with biological injections is inappropriate and can compromise long-term outcomes:

• Severe bone-on-bone angular deformity: In advanced arthritis with severe varus (bow-legged) or valgus (knock-knee) deformity, mechanical malalignment accelerates bone loss and ligament stretching, making eventual surgery technically more complex.
• Fixed flexion contracture: If the knee cannot be fully straightened, walking mechanics deteriorate rapidly, placing compensatory strain on the spine and opposite hip.
• Profound functional decline and muscle wasting: When severe pain forces a patient into prolonged inactivity, quadriceps muscle atrophy and cardiovascular deconditioning develop, which impairs recovery if surgery is eventually undertaken.
• Intractable rest or night pain: Severe pain that interrupts sleep and resists medical management indicates that joint destruction has exceeded the therapeutic window of biological injections.

For patients experiencing these signs, reading our guide on when is it time for knee replacement and understanding what to expect during life after joint replacement can clarify why definitive surgery often represents the safest path to restoring quality of life.

Who Is the Ideal Candidate to Delay Surgery with BMAC?

The patient most likely to benefit from BMAC is someone with moderate knee osteoarthritis (Kellgren–Lawrence grade II–III) who retains reasonable joint alignment, has preserved range of motion, and experiences persistent activity-related discomfort despite conservative measures. In this cohort, biological modulation can provide meaningful symptom relief, allowing the patient to remain active and postpone major surgery by several years.

Signs Generally Regarded as Needing Urgent Medical Evaluation

While osteoarthritis typically follows a slow course, certain acute symptoms require urgent medical evaluation rather than an elective consultation:

• Sudden inability to bear weight on the affected limb.
• Rapid onset of severe joint swelling within hours.
• An acutely locked joint that cannot be straightened.
• Joint swelling accompanied by fever, chills, or spreading skin warmth and redness.

Clinical Consultation and Next Steps

Deciding whether to pursue biological joint preservation or proceed with surgical reconstruction requires an objective, individualised assessment. Weight-bearing radiographs, physical stability testing, and functional evaluation are essential to determine whether BMAC is clinically appropriate.

An in-person consultation with Professor Dr Farooq Azam Khan at his Lahore clinics provides a comprehensive orthopaedic evaluation, helping you navigate the most effective treatment pathway for your joint health.